The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2022Using AZP2006 (Ezeprogind) to Stabilize Progranulin – A Novel Therapeutic Strategy for GBA1-linked Parkinson’s Disease
Study Rationale: Progranulin (PGRN) regulates cell growth, survival and changes. They are usually secreted or transported to the lysosome. Its deficiency and inflammation leads to a decline in the...
-
Research Grant, 2022Development And Validation Of A Miro1 Biomarker Assay Using White Blood Cells
Study Rationale: The mitochondrial protein Miro1 fails to be degraded and this defect impairs mitophagy in more than 90% of all Parkinson’s disease (PD) patients of both genetic and sporadic forms...
-
Research Grant, 2022RT-QuIC Testing of Misfolded α-Synuclein in Stage 4 Study; Submandibular Gland Biopsies and CSF Samples
Study Rationale: Normally folded a-synuclein protein is vital to normal brain function. However, misfolded a-synuclein can form the aggregated fibrils that contribute to Parkinson’s disease’s (PD)...
-
Diversity, Equity and Inclusivity in Parkinson's research, 2022Parkinson’s Disease in Southern Africa
Study Rationale: Most studies on Parkinson’s disease (PD) are focused on patients in Europe and North America. It is crucial to investigate patterns and the causes PD in other parts of the world. It...
-
2022: Accelerated Therapeutics Program, 2022Preclinical and Early Clinical Development of NPT1220-478 for the Treatment of Parkinson's Disease
Study Rationale: Parkinson’s disease is a progressive neurodegenerative disorder; meaning that from its inception, neurons are continuously dying with resulting worsening of neurologic symptoms. Two...
-
Fall 2020 RFA: Therapeutic Pipeline Program-Pre-Clinical, 2022Targeting Colony-stimulating Factor 1 Receptor (CSF1R) to Modify Disease Progression in Preclinical Experimental Models of Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by pronounced neuroimmune dysfunction. Although the disease is very common, no therapy is available...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.